Drugs / Curcugen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07566494 | Jul 2026 → Apr 2027 expected | sickle cell disease | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Curcugen | “VAS-101 contains Curcugen (Registered Trademark) as the active ingredient, with concentrations of 2mg in VAS-101 0.05 mL, 4mg in VAS-101 0.1 mL, and 12mg in VAS-101 0.3 mL” NCT07566494 ↗ |
| Known as | Vasceptor(R) | “The overall objective of this study is to assess the clinical safety and tolerability of a patented, bioavailability-enhanced, transdermal application of curcuminoids, VAS-101...” NCT07566494 ↗ |
| Route | Topical | “a special gel called VAS-101 will be put on the forearms in the clinic two times a week.” NCT07566494 ↗ |